4//SEC Filing
Christenson Johan 4
Accession 0000899243-20-017874
CIK 0001805890other
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 6:37 AM ET
Size
11.8 KB
Accession
0000899243-20-017874
Insider Transaction Report
Form 4
Christenson Johan
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-06-25+30,000→ 30,000 totalExercise: $17.00Exp: 2030-06-18→ Common Shares (30,000 underlying) - Award
Warrants to purchase Class B Preferred Exchangeable Shares
2020-01-10+576,233→ 576,233 total(indirect: See Footnote)Exercise: $1.15From: 2020-01-10Exp: 2022-01-10→ Common Shares (107,929 underlying) - Purchase
Class B Preferred Exchangeable Shares
2020-06-02$1.15/sh+2,856,108$3,288,523→ 5,712,216 total(indirect: See Footnote)→ Common Shares (534,951 underlying)
Footnotes (4)
- [F1]Represents Warrants to Purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will become warrants to purchase Common Shares of the Issuer at an exercise price of $8.10 per share.
- [F2]The securities are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.
- [F3]Represents Class B Preferred Exchangeable Shares of Fusion (Pharmaceuticals) Ireland Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited are redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited will be redeemed into Class B Preferred Shares on a one-for-one basis, which will subsequently convert on a one-for-5.339 basis into the number of Common Shares shown in column 7. The Class B Preferred Exchangeable Shares have no expiration date.
- [F4]This option shall vest and become exercisable in 36 equal monthly installments commencing on July 18, 2020.
Documents
Issuer
Fusion Pharmaceuticals Inc.
CIK 0001805890
Entity typeother
Related Parties
1- filerCIK 0001488771
Filing Metadata
- Form type
- 4
- Filed
- Jun 29, 8:00 PM ET
- Accepted
- Jun 30, 6:37 AM ET
- Size
- 11.8 KB